V-Square Quantitative Management’s Neurocrine Biosciences NBIX Stock Holding History

V-Square Quantitative Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Buy	1,711 +35	+2%	+$4.64K	0.02%	508
2025 Q4	$238K	Buy	+1,676	New	+$243K	0.02%	503
2025 Q3	–	Sell	-1,550	Closed	-$195K	–	430
2025 Q2	$195K	Buy	1,550 +31	+2%	+$3.56K	0.03%	502
2025 Q1	$168K	Buy	1,519 +92	+6%	+$11.7K	0.02%	521
2024 Q4	$195K	Buy	1,427 +9	+0.6%	+$1.11K	0.03%	512
2024 Q3	$163K	Buy	1,418 +82	+6%	+$11.2K	0.02%	525
2024 Q2	$184K	Buy	+1,336	New	+$183K	0.03%	511
2023 Q3	–	Sell	-143	Closed	-$13.5K	–	555
2023 Q2	$13.5K	Buy	+143	New	+$14K	0.01%	404

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

V-Square Quantitative Management's NBIX Position: Q1 2026 in Review

V-Square Quantitative Management increased its Neurocrine Biosciences (NBIX) stake by 2.1% in Q1 2026, buying an estimated $4.64K and bringing the position to 1,711 shares worth $225K. The position accounts for 0.02% of the portfolio, ranked #508.

V-Square Quantitative Management first reported a position in NBIX in Q2 2023 and has held it in 8 quarters since. The position peaked at $238K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

V-Square Quantitative Management held 1,711 shares of Neurocrine Biosciences worth $225K as of Q1 2026.
V-Square Quantitative Management bought 35 Neurocrine Biosciences shares in Q1 2026, an estimated $4.64K.
Neurocrine Biosciences made up 0.02% of V-Square Quantitative Management's portfolio in Q1 2026, its #508 holding.
V-Square Quantitative Management first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 8 quarters since.
V-Square Quantitative Management's Neurocrine Biosciences position peaked at $238K in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on V-Square Quantitative Management's 13F filing for Q1 2026, filed 27 Apr 2026.